Zinc and its compounds

Information sheet

These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on the zinc moiety and therefore considers all zinc compounds on the Domestic Substances List (DSL) that may release zinc as well as zinc in its elemental form, and zinc released in the environment in dissolved, solid or particulate forms. It includes, but is not limited to the 75 substances identified in the table below.

Summary of publications
CAS RN Chemical substance Additional risk characterization document Draft screening assessment Risk management scope Proposed conclusion on section 64 criteria Follow-up activities
127-82-2 Benzenesulfonic acid, 4-hydroxy-, zinc salt (2:1) HTML HTML HTML Zinc and soluble zinc compounds meet one or more of the criteria Refer to risk management scope
136-23-2 Zinc, bis(dibutylcarbamodithioato-S,S')-, (T-4)-
136-53-8 Hexanoic acid, 2-ethyl-, zinc salt
155-04-4 2(3H)-Benzothiazolethione, zinc salt
546-46-3Table 1 Footnote 1 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, zinc salt (2:3)
556-38-7Table 1 Footnote 1 Pentanoic acid, zinc salt (2:1)
557-05-1 Octadecanoic acid, zinc salt
557-07-3 9-Octadecenoic acid (Z)-, zinc salt
557-08-4 10-Undecenoic acid, zinc salt
557-34-6 Acetic acid, zinc salt
1314-13-2 Zinc oxide (ZnO)
1314-22-3 Zinc peroxide (Zn(O2))
1314-84-7Table 1 Footnote 1 Zinc phosphide (Zn3P2)
1314-98-3 Zinc sulfide (ZnS)
1345-05-7 C.I. Pigment White 5
1405-89-6Table 1 Footnote 1 Bacitracin Zinc
1434719-44-4Table 1 Footnote 1 Dodecanoic acid, zinc salt
3486-35-9 Carbonic acid, zinc salt (1:1)
36393-20-1Table 1 Footnote 1 Zincate(2-), bis[L-aspartato(2-)-.kappa.N,.kappa.O1]-, dihydrogen, (T-4)-
4259-15-8 Zinc, bis[O,O-bis(2-ethylhexyl) phosphorodithioato-S,S']-, (T-4)-
4468-02-4 Zinc, bis(D-gluconato-O1,O2)-
5970-45-6 Acetic acid, zinc salt, dihydrate
7446-19-7 Sulfuric acid, zinc salt (1:1), monohydrate
7446-20-0 Sulfuric acid, zinc salt (1:1), heptahydrate
7446-26-6 Diphosphoric acid, zinc salt (1:2)
7646-85-7 Zinc chloride (ZnCl2)
7733-02-0 Sulfuric acid, zinc salt (1:1)
7779-88-6 Nitric acid, zinc salt
7779-90-0 Phosphoric acid, zinc salt (2:3)
8011-96-9 Calamine (pharmaceutical preparation)
8048-07-5 C.I. Pigment Yellow 35
10139-47-6Table 1 Footnote 1 Zinc iodide (ZnI2)
11103-86-9 Chromate(1-), hydroxyoctaoxodizincatedi-, potassium
12001-85-3 Naphthenic acids, zinc salts
12122-17-7 Hydrozincite (Zn5(CO3)2(OH)6)
12442-27-2 Cadmium zinc sulfide ((Cd,Zn)S)
13189-00-9 2-Propenoic acid, 2-methyl-, zinc salt
13463-41-7 Zinc, bis(1-hydroxy-2(1H)-pyridinethionato-O,S)-, (T-4)-
13530-65-9 Chromic acid (H2CrO4), zinc salt (1:1)
13598-37-3 Phosphoric acid, zinc salt (2:1)
14324-55-1 Zinc, bis(diethylcarbamodithioato-S,S')-, (T-4)-
14476-25-6 Smithsonite (Zn(CO3))
14726-36-4 Zinc, bis[bis(phenylmethyl)carbamodithioato-S,S']-, (T-4)-
15337-18-5 Zinc, bis(dipentylcarbamodithioato-S,S')-, (T-4)-
15454-75-8Table 1 Footnote 1 Zinc, bis(5-oxo-L-prolinato-.kappa.N1,.kappa.O2)-, (T-4)-
16260-27-8 Tetradecanoic acid, zinc salt
16283-36-6 Zinc, bis(2-hydroxybenzoato-O1,O2)-, (T-4)-
16871-71-9 Silicate(2-), hexafluoro-, zinc (1:1)
17949-65-4Table 1 Footnote 1 Zinc, bis(2-pyridinecarboxylato-.kappa.N1,.kappa.O2-, (T-4)-
19210-06-1 Phosphorodithioic acid, zinc salt
20427-58-1 Zinc hydroxide (Zn(OH)2)
24308-84-7 Benzenesulfinic acid, zinc salt
24887-06-7 Zinc, bis(hydroxymethanesulfinato-OS,O1)-, (T-4)-
27253-29-8 Neodecanoic acid, zinc salt
28016-00-4 Naphthalenesulfonic acid, dinonyl-, zinc salt
28629-66-5 Zinc, bis(O,O-diisooctyl phosphorodithioato-S,S')-
37300-23-5 C.I. Pigment Yellow 36
38714-47-5 Zinc(2++), tetraammine-, (T-4)-, carbonate (1:1)
40861-29-8 Carbonic acid, ammonium zinc salt (2:2:1)
49663-84-5 Zinc chromate hydroxide (Zn5(CrO4)(OH)8)
50922-29-7 Chromium zinc oxide
51810-70-9Table 1 Footnote 1 Zinc phosphide
61617-00-3 2H-Benzimidazole-2-thione, 1,3-dihydro-4(or 5)-methyl-, zinc salt (2:1)
68457-79-4 Phosphorodithioic acid, mixed O,O-bis(iso-Bu and pentyl) esters, zinc salts
68611-70-1 Zinc sulfide (ZnS), copper chloride-doped
68649-42-3 Phosphorodithioic acid, O,O-di-C1-14-alkyl esters, zinc salts
68784-31-6 Phosphorodithioic acid, mixed O,O-bis(sec-Bu and 1,3-dimethylbutyl) esters, zinc salts
68918-69-4 Petrolatum (petroleum), oxidized, zinc salt
68988-45-4 Phosphorodithioic acid, mixed O,O-bis(2-ethylhexyl and iso-Bu and pentyl) esters, zinc salts
73398-89-7 Xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]-, (T-4)-tetrachlorozincate(2-) (2:1)
84605-29-8 Phosphorodithioic acid, mixed O,O-bis(1,3-dimethylbutyl and iso-Pr) esters, zinc salts
85940-28-9 Phosphorodithioic acid, mixed O,O-bis(2-ethylhexyl and iso-Bu and iso-Pr) esters, zinc salts
102868-96-2Table 1 Footnote 1 Zinc, bis[N-(acetyl-.kappa.O)-L-methioninato-.kappa.O]-, (T-4)-
113706-15-3 Phosphorodithioic acid, mixed O,O-bis(sec-Bu and isooctyl) esters, zinc salts
Table 1 Footnote 1

Substance identified for further consideration following prioritization of the Revised In Commerce List.

Table 1 Return to footnote 1 referrer

Additional risk characterization document

The Additional Risk Characterization Document in Support of the Draft Screening Assessment for Zinc and its Compounds: Pulp and paper sector exposure and risk characterization was published on June 25, 2021. The document contains new information pertaining to releases of zinc from the pulp and paper sector identified since publication of the draft screening assessment.

The document has been published to provide the public with the opportunity to comment on the new information, prior to it being considered in the final screening assessment of zinc and its compounds, and if appropriate, the corresponding proposed risk management approach.

Comments or information submitted with respect to the risk characterization document must cite the title of the document, along with the date of publication, and can be provided to the Minister of the Environment until August 24, 2021, using one of the following methods:

In accordance with section 313 of the Canadian Environmental Protection Act, 1999, any person who provides information in response to this publication may submit with the information a request that it be treated as confidential.

Date Activity
June 2022 Anticipated publication of the final screening assessment and proposed risk management approach.
June 25, 2021 Publication and start of 60-day public comment period on the additional risk characterization document.
June 29, 2019 Publication and start of 60-day public comment period on the draft screening assessment and the risk management scope. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 26.

Page details

Date modified: